New scientific trials confirmed that Pfizer's COVID-19 vaccine elicits "100% efficacy and sturdy antibody responses" in adolescents from 12-15 years outdated, the drug firm introduced Wednesday. The trial included 2,260 trial individuals; the outcomes are even higher than earlier responses from individuals ages 16-25.
Pfizer and its vaccine associate BioNTech say they'll submit the outcomes "as quickly as potential" to the U.S. Meals and Drug Administration and the European Medicines Company, asking regulators to broaden their authorizations for the vaccine's use in younger folks.
Pfizer will submit the information "within the coming weeks," Pfizer CEO and Chairman Albert Bourla mentioned in a information launch in regards to the trial. Calling the outcomes encouraging, he added that the corporate is appearing "with the hope of beginning to vaccinate this age group earlier than the beginning of the following faculty 12 months."
Throughout the scientific trial, 18 individuals who had been within the placebo group developed COVID-19, whereas not one of the folks within the vaccinated group did. Blood checks confirmed a powerful immune system response one month after individuals acquired the second vaccine dose, based on a abstract of check information launched by Pfizer.
As for potential negative effects, Pfizer mentioned the vaccine was tolerated nicely within the Section 3 trial.